Table 2.
Changes in the neuropathy symptom score, the neuropathy disability score, and the sum of both comparing baseline and week 12 and week 24 in the full analysis set population
| ALC (n = 117) | MC (n = 115) | P‐value: change in ALC vs MC | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Week 12 | Week 24 | Change from baseline to week 24 | P‐value: baseline vs week 24 | Baseline | Week 12 | Week 24 | Change from baseline to week 24 | P‐value: baseline vs week 24 | ||
| NSS+NDS | 13.10 ± 2.80 | 10.50 ± 3.78 | 9.09 ± 4.24 | 4.01 ± 3.25 | <0.0001 | 12.79 ± 2.80 | 10.51 ± 3.70 | 9.33 ± 4.34 | 3.46 ± 3.43 | <0.0001 | 0.14 |
| NSS | 6.52 ± 1.52 | 4.95 ± 2.21 | 4.17 ± 2.45 | 2.35 ± 2.23 | <0.0001 | 6.37 ± 1.71 | 4.94 ± 2.12 | 4.25 ± 2.60 | 2.11 ± 2.48 | <0.0001 | 0.38 |
| NDS | 6.58 ± 2.19 | 5.55 ± 2.50 | 4.92 ± 2.62 | 1.66 ± 1.90 | <0.0001 | 6.43 ± 2.04 | 5.57 ± 2.37 | 5.08 ± 2.41 | 1.35 ± 1.65 | <0.0001 | 0.23 |
All continuous variables were presented as mean ± standard deviation. All comparisons were analyzed by t‐test. ALC, acetyl‐L‐carnitine; MC, methylcobalamin; NDS, neuropathy disability score; NSS, neuropathy symptom score.